ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OMDA vs STLN // EV/EBITDA & P/E VALUATION

Omada Health Inc. (NASDAQ) VS. Starling Oncology Inc. (NASDAQ) • 15-METRIC TALLY: OMDA 7 — STLN 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OMDA VS. STLN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OMDA STLN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 65.70% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -15.70% -35.00% +19.30 OMDA /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield 1.41% -4.10% +5.51 OMDA /fcf-yield <GO>
Operating Margin -4.60% -7.20% +2.60 OMDA /operating-margins <GO>
Net Profit Margin -4.90% 68.00% -72.90 STLN /net-margins <GO>
Revenue Growth (YoY) 53.20% 27.80% +25.40 OMDA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 8.93 2.58 +6.35 OMDA /balance-sheet <GO>
Piotroski F-Score Quality 7/9 3/9 +4.00 OMDA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.6 49.5 -5.90 STLN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.20B $677.7M $525.2M OMDA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OMDA REV STLN REV OMDA GROSS % STLN GROSS % OMDA FCF STLN FCF
FY 2025 $260.2M $502.7M 65.7% — $16.9M -$27.8M
FY 2024 $169.8M $393.4M 60.6% — -$34.8M -$30.3M
FY 2023 $122.8M $324.2M — — -$49.7M -$36.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OMDA // BETA —
STLN // BETA —